The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
A high-stakes suit this month by the federal government against Community Health Network is raising questions about when they are proper and when they cross the line.
The bill, sponsored by Rep. Ed Soliday, R-Valparaiso, comes as several large Indiana utilities are planning to shut down thousands of megawatts of coal-fired generating capacity in coming years in favor of cleaner or cheaper fuel sources.
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
After raking in record amounts of venture capital funding in 2017 and 2018, Indiana life science companies saw funding drop last year by double-digits, while the average deal amount dipped sharply as well.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
The eight-year-old biotech startup is developing treatments for gastrointestinal disorders, and last year hired a new CEO. It’s unclear how many employees remain in Indiana, or how much longer the company will keep a local office.
The judge vacated a $3 million jury award against Cook Medical, saying a Georgia woman who sued the Bloomington-based device maker “did not have overwhelming evidence” to show the company’s implanted blood-clot filter was defective or caused her injuries.
The Justice Department said the financial arrangements were outlined in a whistleblower suit brought by Thomas Fischer, who served as Community Health’s CFO from 2005 until his sudden exit in 2013. In a separate suit, Fischer claimed he was fired in retaliation for questioning possibly illegal practices.
A bill that tries to address surprise out-of-network fees was among several health care-related measures proposed Monday by Indiana lawmakers during the first day of the General Assembly.
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
The new menu will feature new twists on old dishes, such as meatloaf and fried chicken, and the decor will get a freshening-up, although there are no plans to expand seating.
The year didn’t feature any hostile takeovers or huge disasters. But a lot of companies made big strides in 2019, including Eli Lilly and Co., Corteva and Elanco. And many rejoiced when Washington ended a 2.3% tax on thousands of medical devices.
It will be the third Indiana location for Fort Wayne-based Eddie Merlot’s, which plans to take over space in one of downtown’s oldest buildings vacated last year by Red the Steakhouse.
The repeal ends a 2.3% tax on thousands of medical devices, from stents and catheters to pacemakers and MRI machines. Indiana is home to 155 device-makers, ranging from small metal shops to multibillion-dollar manufacturers.
For the Lilly Endowment, a good year means it’s time to cash in.
CEO Gail Boudreaux’s recent comments at a health care summit dampened speculation that Anthem might create its own physician group, something the insurer tried unsuccessfully two decades ago.
Neuropsychiatric Hospitals LLC said it is developing a 64-bed hospital in Greenwood that will serve patients with complex medical and psychiatric condition.
The Petersburg Generating Station, about 120 miles southwest of Indianapolis, has been called a “super polluter” by environmental groups, with violations for excess sulfur dioxide, nitrous oxide particulate matter and sulfuric mist.